Literature DB >> 29076508

Challenging metastatic breast cancer with the natural defensin PvD1.

Tiago N Figueira1, Filipa D Oliveira1, Inês Almeida1, Érica O Mello2, Valdirene M Gomes2, Miguel A R B Castanho1, Diana Gaspar1.   

Abstract

Metastatic breast cancer is a very serious life threatening condition that poses many challenges for the pharmaceutical development of effective chemotherapeutics. As the therapeutics targeted to the localized masses in breast improve, metastatic lesions in the brain slowly increase in their incidence compromising successful treatment outcomes overall. The blood-brain-barrier (BBB) is one important obstacle for the management of breast cancer brain metastases. New therapeutic approaches are in demand for overcoming the BBB's breaching by breast tumor cells. In this work we demonstrate the potential dual role of a natural antimicrobial plant defensin, PvD1: it interferes with the formation of solid tumors in the breast and concomitantly controls adhesion of breast cancer cells to human brain endothelial cells. We have used a combination of techniques that probe PvD1's effect at the single cell level and reveal that this peptide can effectively damage breast tumor cells, leaving healthy breast and brain cells unaffected. Results suggest that PvD1 quickly internalizes in cancer cells but remains located in the membrane of normal cells with no significant damage to its structure and biomechanical properties. These interactions in turn modulate cell adhesiveness between tumor and BBB cells. PvD1 is a potential template for the design of innovative pharmacological approaches for metastatic breast cancer treatment: the manipulation of the biomechanical properties of tumor cells that ultimately prevent their attachment to the BBB.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29076508     DOI: 10.1039/c7nr05872a

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  5 in total

1.  The antimetastatic breast cancer activity of the viral protein-derived peptide vCPP2319 as revealed by cellular biomechanics.

Authors:  Filipa D Oliveira; Marco Cavaco; Tiago N Figueira; Javier Valle; Vera Neves; David Andreu; Diana Gaspar; Miguel A R B Castanho
Journal:  FEBS J       Date:  2021-11-07       Impact factor: 5.622

2.  A novel recombinant javanicin with dual antifungal and anti-proliferative activities.

Authors:  Santhasiri Orrapin; Amornrat Intorasoot; Sittiruk Roytrakul; Nathupakorn Dechsupa; Jiraporn Kantapan; Yanika Onphat; Chutima Srimek; Chayada Sitthidet Tharinjaroen; Usanee Anukool; Bordin Butr-Indr; Ponrut Phunpae; Sorasak Intorasoot
Journal:  Sci Rep       Date:  2019-12-05       Impact factor: 4.379

3.  Human β-Defensin 2 (HBD-2) Displays Oncolytic Activity but Does Not Affect Tumour Cell Migration.

Authors:  Guneet K Bindra; Scott A Williams; Fung T Lay; Amy A Baxter; Ivan K H Poon; Mark D Hulett; Thanh Kha Phan
Journal:  Biomolecules       Date:  2022-02-06

Review 4.  Defensin-lipid interactions in membrane targeting: mechanisms of action and opportunities for the development of antimicrobial and anticancer therapeutics.

Authors:  Matthew J A Hein; Marc Kvansakul; Fung T Lay; Thanh Kha Phan; Mark D Hulett
Journal:  Biochem Soc Trans       Date:  2022-02-28       Impact factor: 4.919

5.  Improved smallest peptides based on positive charge increase of the γ-core motif from D1 and their mechanism of action against Candida species.

Authors:  Érica de Oliveira Mello; Gabriel Bonan Taveira; André de Oliveira Carvalho; Valdirene Moreira Gomes
Journal:  Int J Nanomedicine       Date:  2019-01-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.